hVIVO H1 2026 Results Update
"The first half of 2026 saw a clear improvement in commercial momentum. With proposal volumes ramping up and our contracted contracted orderbook more than doubling since the start of the year, the growing demand across our integrated early clinical development platform is very evident. Our record orderbook now provides us with good revenue visibility and positions the Group for significant revenue growth in 2027.”
Yamin 'Mo' Khan
CEO at hVIVO
Our Purpose
Accelerate the development of safe and effective medicines that improve the lives of people around the world.
Our Mission
To constantly pursue new ways to reduce the time, risk and cost of bringing much needed life-changing medicines to market
hVIVO plc Annual Report & Accounts 2025
Download and read the 2025 Annual Report
